X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis

Cytokine and Growth Factor Reviews

Volumn 12, Issue 2-3, 2001, Pages 189-205

  Diao, Jingyu ^a   Garces, Robert ^a   Richardson, Christopher D ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; ENZYME ACTIVATOR; GROWTH FACTOR; GROWTH PROMOTOR; HEPATITIS B VIRUS X PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P53; PROTEIN X; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANS ACTIVATORS; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; VIRUS PROTEIN;

ANIMAL; APOPTOSIS; CELL SURVIVAL; ENZYME ACTIVATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER REGENERATION; LIVER TUMOR; MITOCHONDRION; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRUS INFECTION;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CYTOKINES; GROWTH SUBSTANCES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER; LIVER NEOPLASMS; LIVER REGENERATION; NF-KAPPA B; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

CARINOMA; HEPATITIS B VIRUS; JANUS;

EID: 0034954277     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(00)00034-4     Document Type: Review

References (187)

1. Tree squirrel hepatitis B virus: Antigenic and structural characterization
2. Landmark article Feb 15, 1965: A 'new' antigen in leukemia sera
3. Application of radiolabeled anti-HBx monoclonal antibody for HCC targeting therapy
4. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan
5. Biology of hepatitis B virus
6. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma
7. Serologic evaluation of viral hepatitis
8. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication
9. Cytotoxic T cells and viral hepatitis
10. Hepatitis B virus immunopathogenesis
11. Diagnosis, therapy and prognosis of viral hepatitis
12. Hepatitis B virus transgenic mice: Insights into the virus and the disease
13. Virus-induced anti-asialoglycoprotein receptor autoimmunity in experimental hepadnaviral hepatitis
14. Complement-mediated cytotoxicity and inhibition of ligand binding to hepatocytes by woodchuck hepatitis virus-induced autoantibodies to asialoglycoprotein receptor
15. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice
16. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice
17. Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11-base-pair direct repeat
18. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma
19. Cloning and structural analysis of integrated woodchuck hepatitis virus sequences from hepatocellular carcinomas of woodchucks
20. Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma
21. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma
22. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma
23. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma
24. Effects of cytokines on the liver
25. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections
26. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: Lessons from hepatitis B
27. Hepatitis B virus X protein activates expression of IGF-IR and VEGF in hepatocellular carcinoma cells
28. Hepatocytes and scatter factor
29. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction
30. Scatter factor/hepatocyte growth factor is essential for liver development
31. c-jun is essential for normal mouse development and hepatogenesis
32. Hepatocyte growth factor (hepatoprotein A) rapidly increases in plasma before DNA synthesis and liver regeneration stimulated by partial hepatectomy and carbon tetrachloride administration
33. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: Evidence for rapid decay of the 8 kb c-MET transcript
34. Alteration of epidermal growth factor-dependent phosphorylation during rat liver regeneration
35. Effect of secretin and glucagon on Brunner's gland secretion in the rat
36. Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration
37. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a japanese population: Involvement of HBx and p53
38. Development of liver tumors in transforming growth factor alpha transgenic mice
39. Liver regeneration in fulminant hepatitis as evaluated by serum transforming growth factor alpha levels
40. Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice
41. Liver regeneration and hepatocarcinogenesis in transforming growth factor-alpha-targeted mice
42. Uptake and distribution of hepatocyte growth factor in normal and regenerating adult rat liver
43. Tumor necrosis factor-alpha induces c-jun during the regenerative response to liver injury
44. Kupffer cell depletion by gadolinium chloride enhances liver regeneration after partial hepatectomy in rats
45. Initiation of liver growth by tumor necrosis factor: Deficient liver regeneration in mice lacking type I tumor necrosis factor receptor
46. Delayed Fas-mediated hepatocyte apoptosis during liver regeneration in mice: Hepatoprotective role of TNF alpha
47. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: Interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro
48. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6
49. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice
50. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent
51. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
52. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: Support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway
53. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways
54. Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor
55. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies
56. Transforming growth factor beta in tissue fibrosis
57. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
58. Dysregulation of apoptosis in hepatocellular carcinoma
59. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha
60. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor beta 1
61. Apoptosis is induced by transforming growth factor-beta 1 within 5 hours in regressing liver without significant fragmentation of the DNA
62. Inhibition of rat hepatocyte proliferation by transforming growth factor beta and glucagon is associated with inhibition of ERK2 and p70 S6 kinase
63. Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: Involvement of reactive oxygen intermediates
64. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis
65. The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor alpha-mediated rat hepatocyte survival and apoptosis
66. TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes
67. Induction of apoptosis by transforming growth factor-beta 1 in the rat hepatoma cell line McA-RH7777: A possible association with tissue transglutaminase expression
68. The retinoblastoma gene product inhibits TGF-beta1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells
69. Processing/activation of CPP32-like proteases is involved in transforming growth factor beta 1-induced apoptosis in rat hepatocytes
70. Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells
71. Modulation of life and death by the TNF receptor superfamily
72. ICE-like proteases in apoptosis
73. Rel/NF-kappa B/I kappa B story
74. Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-kappa B activation
75. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase
76. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation
77. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways
78. Proteases to die for
79. Mitochondrial control of cell death
80. The little devil of death
81. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
82. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
83. Cellular survival: A play in three Akts
84. The PI-3-kinase/Akt signaling pathway delivers an anti-apoptotic signal
85. Modulation of cellular apoptotic potential: Contributions to oncogenesis
86. PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond
87. NF-kappa B: A lesson in family values
88. NF-kappaB activation and HIV-1 induced apoptosis
89. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B
90. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice
91. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice
92. The stress-activated protein kinase pathways
93. Adenovirus E1B 19,000-molecular-weight protein activates c-jun N-terminal kinase and c-jun-mediated transcription
94. Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4
95. The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic
96. Signal transduction through MAP kinase cascades
97. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
98. The role of p21ras in receptor tyrosine kinase signalling
99. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
100. STATs in oncogenesis
101. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
102. Jak-STAT signaling induced by the v-abl oncogene
103. Functional roles of STAT family proteins: Lessons from knockout mice
104. The molecular biology of the hepatitis B viruses
105. Antibodies to peptides detect new hepatitis B antigen: Serological correlation with hepatocellular carcinoma
106. Common evolutionary origin of hepatitis B virus and retroviruses
107. The hepatitis B virus-encoded transcriptional trans-activator hbx appears to be a novel protein serine/threonine kinase
108. X antigen polypeptides in the sera of hepatitis B virus-infected patients
109. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma
110. Immune reactions against hepatitis B viral antigens lead to the rejection of hepatocellular carcinoma in BALB/c mice
111. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection
112. X region deletion variants of hepatitis B virus in surface antigen-negative infections and non-A, non-B hepatitis
113. Hepatitis B virus X gene 1751 to 1764 mutations: Implications for HBeAg status and disease
114. HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis
115. Hepatitis B virus HBx gene and hepatocarcinogenesis
116. HBx gene of hepatitis B virus induces liver cancer in transgenic mice
117. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice
118. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene
119. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice
120. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA
121. In vitro tumorigenicity of hepatitis B virus DNA and HBx protein
122. Properties of tumour suppressor p53 in murine hepatocyte lines transformed by hepatitis B virus X protein
123. Differential immediate early gene expression in conditional hepatitis B virus Px-transforming versus nontransforming hepatocyte cell lines
124. The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells
125. Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation
126. X-gene product of hepatitis B virus induces apoptosis in liver cells
127. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx
128. Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts
129. Mouse monoclonal antibody directed against hepatitis B virus X protein synthesized in Escherichia coli: Detection of reactive antigen in liver cell carcinoma and chronic hepatitis
130. Hepatitis B virus (HBV) X gene expression in human cells and anti-HBx antibodies detection in chronic HBV infection
131. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors
132. The X protein of the hepatitis B virus acts as a transcription factor when targeted to its responsive element
133. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3
134. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation
135. The X protein of hepatitis B virus coactivates potent activation domains
136. The hepatitis B virus transactivator protein, HBx, interacts with single-stranded DNA (ssdna). Biochemical characterizations of the HBx-ssDNA interactions
137. Px, the HBV-encoded coactivator, interacts with components of the transcription machinery and stimulates transcription in a TAF-independent manner
138. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors
139. Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C
140. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis
141. Selective transcriptional regulations in the human liver cell by hepatitis B viral X protein
142. Px, the HBV-encoded coactivator, suppresses the phenotypes of TBP and TAFII250 mutants
143. Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator Px
144. The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB
145. Dissociation of DDB1-binding and transactivation properties of the hepatitis B virus X protein
146. Hepatitis B virus X protein interferes with cellular DNA repair
147. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases
148. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway
149. The hepatitis B virus transactivator HBx causes elevation of diacylglycerol and activation of protein kinase C
150. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade
151. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-jun N-terminal mitogen-activated protein kinases
152. Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins
153. The hepatitis B virus X-associated protein, XAP3, is a protein kinase C-binding protein
154. Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements
155. Hepatitis B virus transactivator MHBst: Activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization
156. Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway
157. Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha
158. Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product
159. Immunohistochemical study of hepatitis C virus core antigen and HBxAg in liver cirrhosis and hepatocellular carcinoma tissues
160. Erk-independent partial activation of AP-1 sites by the hepatitis B virus HBx protein
161. Src kinases involved in hepatitis B virus replication
162. Hepatitis B virus X protein inhibits transforming growth factor-beta-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway
163. HBx protein of hepatitis B virus activates Jak1-STAT signaling
164. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: Implications of IGF-I receptor gene activation by hepatitis B virus X gene product
165. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation
166. Regulation of p53-dependent apoptosis by E1A and E1B
167. Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53
168. Sindbis virus induces apoptosis through a caspase-dependent, CrmA-sensitive pathway
169. CrmA-inhibitable cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein during Fas- and tumor necrosis factor-induced apoptosis
170. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death
171. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak
172. TNF-alpha signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K
173. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls
174. Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts
175. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis
176. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene
177. The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines
178. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro
179. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma
180. Functional inactivation but not structural mutation of p53 causes liver cancer
181. Induction of apoptosis after switch-on of the hepatitis B virus X gene mediated by the Cre/loxP recombination system
182. Oncogenic potential of hepatitis B virus
183. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation
184. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage
185. Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death
186. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential
187. X Protein of hepatitis B virus inhibits FAS-mediated apoptosis and is associated with upregulation of the SAPK/JNK pathway